These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24783515)

  • 41. [Silica-coated ethosome as a novel oral delivery system for enhanced oral bioavailability of curcumin].
    Li C; Deng L; Zhang Y; Su TT; Jiang Y; Chen ZB
    Yao Xue Xue Bao; 2012 Nov; 47(11):1541-7. PubMed ID: 23387090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
    Wang X; Chen Y; Dahmani FZ; Yin L; Zhou J; Yao J
    Biomaterials; 2014 Aug; 35(26):7654-65. PubMed ID: 24927684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma.
    Gong C; Xie Y; Wu Q; Wang Y; Deng S; Xiong D; Liu L; Xiang M; Qian Z; Wei Y
    Nanoscale; 2012 Sep; 4(19):6004-17. PubMed ID: 22910790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Self-aggregated nanoparticles of linoleic acid-modified glycol chitosan conjugate as delivery vehicles for paclitaxel: preparation, characterization and evaluation.
    Yu J; Liu Y; Zhang L; Zhao J; Ren J; Zhang L; Jin Y
    J Biomater Sci Polym Ed; 2015; 26(18):1475-89. PubMed ID: 26489688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studies on lactoferrin nanoparticles of gambogic acid for oral delivery.
    Zhang ZH; Wang XP; Ayman WY; Munyendo WL; Lv HX; Zhou JP
    Drug Deliv; 2013 Feb; 20(2):86-93. PubMed ID: 23495734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
    Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
    J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deoxycholic acid-modified chitooligosaccharide/mPEG-PDLLA mixed micelles loaded with paclitaxel for enhanced antitumor efficacy.
    Jiang C; Wang H; Zhang X; Sun Z; Wang F; Cheng J; Xie H; Yu B; Zhou L
    Int J Pharm; 2014 Nov; 475(1-2):60-8. PubMed ID: 25152167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges.
    Torne SJ; Ansari KA; Vavia PR; Trotta F; Cavalli R
    Drug Deliv; 2010 Aug; 17(6):419-25. PubMed ID: 20429848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
    Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
    Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation.
    Zhang P; Hu L; Yin Q; Zhang Z; Feng L; Li Y
    J Control Release; 2012 May; 159(3):429-34. PubMed ID: 22306333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats.
    Zhao M; Chang J; Fu X; Liang C; Liang S; Yan R; Li A
    J Drug Target; 2012 Jun; 20(5):416-21. PubMed ID: 22519867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles.
    Agüeros M; Zabaleta V; Espuelas S; Campanero MA; Irache JM
    J Control Release; 2010 Jul; 145(1):2-8. PubMed ID: 20347897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; van Tellingen O; Duchin K; Ten Bokkel Huinink WW; Swart M; Lieverst J; Schellens JH
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system.
    Baek JS; So JW; Shin SC; Cho CW
    Int J Mol Med; 2012 Oct; 30(4):953-9. PubMed ID: 22859311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
    Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
    Yang T; Choi MK; Cui FD; Kim JS; Chung SJ; Shim CK; Kim DD
    J Control Release; 2007 Jul; 120(3):169-77. PubMed ID: 17586082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
    Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
    Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.